SLC5A2 and type 2 diabetes mellitus: Four out of five patients (81.3%) were on biguanides, 18.4% on insulin, 6.4% on DDP4, 0.8% on GLP1 and 3.8% of SGLT2; no differences were found regarding drug treatment between controlled and uncontrolled T2DM (not shown).